NIPRO CORP.
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical-Related business develops, manufactures, and sells injection and infusion products, artificial organ-related products, functional products, dialysis products, cell cultures, hospital products, diabetic products, and pharmaceuticals comprising generic and… Read more
NIPRO CORP. (5FA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, NIPRO CORP. (5FA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NIPRO CORP. - Net Assets Trend (None–None)
This chart illustrates how NIPRO CORP.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NIPRO CORP. (None–None)
The table below shows the annual net assets of NIPRO CORP. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to NIPRO CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
NIPRO CORP. Competitors by Market Cap
The table below lists competitors of NIPRO CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GEORGIA CAPITAL LS 001
F:2IX
|
$1.18 Billion |
|
CBIZ Inc
NYSE:CBZ
|
$1.18 Billion |
|
TriMas Corporation
NASDAQ:TRS
|
$1.18 Billion |
|
Tecnoglass Inc
NYSE:TGLS
|
$1.18 Billion |
|
ZF Commercial Vehicle Control Systems India Limited
NSE:ZFCVINDIA
|
$1.18 Billion |
|
Yankey Engineering Co Ltd
TW:6691
|
$1.18 Billion |
|
Isiklar Enerji ve Yapi Holding AS
IS:IEYHO
|
$1.18 Billion |
|
IFAST CORP. LTD
F:1O3
|
$1.18 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NIPRO CORP.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares NIPRO CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently NIPRO CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares NIPRO CORP.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $9,394,036,854
- Average return on equity (ROE) among peers: 4.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NIPRO CORP. (5FA) | €- | N/A | N/A | $1.18 Billion |
| Modern Dental Group Limited (1MD) | $2.36 Billion | 15.30% | 0.55x | $193.75 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $482.88 Million |
| Alcon Inc. (2U3) | $19.26 Billion | 1.95% | 0.45x | $33.73 Billion |
| Shofu Inc. (69W) | $35.51 Billion | 8.83% | 0.23x | $215.32 Million |
| 7VG (7VG) | $176.36 Million | 14.92% | 1.12x | $684.88 Million |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $2.79 Million |
| Paul Hartmann AG (PHH2) | $690.37 Million | 10.65% | 0.81x | $776.29 Million |
| Sartorius AG VZO O.N. (SRT) | $497.08 Million | 9.76% | 1.56x | $6.78 Billion |
| Shandong Weigao Group Medical Polymer Company Limited (UK2) | $25.34 Billion | 8.16% | 0.37x | $1.36 Billion |